CRIS Current Research Information System

CASTELLUCCI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.132
AS - Asia 9.132
EU - Europa 6.838
AF - Africa 621
SA - Sud America 463
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 27.195
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.017
VN - Vietnam 2.770
SG - Singapore 2.367
CN - Cina 2.137
GB - Regno Unito 1.791
DE - Germania 965
IT - Italia 891
SE - Svezia 858
HK - Hong Kong 642
FR - Francia 469
IN - India 412
RU - Federazione Russa 392
UA - Ucraina 332
BR - Brasile 316
IE - Irlanda 278
FI - Finlandia 175
ZA - Sudafrica 160
NL - Olanda 154
TG - Togo 154
CI - Costa d'Avorio 143
KR - Corea 143
JP - Giappone 136
EE - Estonia 122
CH - Svizzera 111
JO - Giordania 104
BG - Bulgaria 81
CA - Canada 80
SC - Seychelles 69
AR - Argentina 66
PH - Filippine 55
BD - Bangladesh 49
NG - Nigeria 47
TH - Thailandia 42
PL - Polonia 41
ID - Indonesia 40
BE - Belgio 38
IQ - Iraq 36
TR - Turchia 35
AT - Austria 32
IR - Iran 32
ES - Italia 31
TW - Taiwan 26
MX - Messico 21
EC - Ecuador 20
SA - Arabia Saudita 16
HR - Croazia 14
PK - Pakistan 14
CL - Cile 12
CO - Colombia 12
VE - Venezuela 12
CZ - Repubblica Ceca 11
LT - Lituania 11
MY - Malesia 11
UZ - Uzbekistan 11
MA - Marocco 9
PY - Paraguay 9
GR - Grecia 8
TN - Tunisia 8
LB - Libano 7
PE - Perù 7
RO - Romania 7
EG - Egitto 6
KZ - Kazakistan 6
MN - Mongolia 6
SK - Slovacchia (Repubblica Slovacca) 6
BO - Bolivia 5
ET - Etiopia 5
NP - Nepal 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
CY - Cipro 4
HU - Ungheria 4
PT - Portogallo 4
BJ - Benin 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
KE - Kenya 3
LY - Libia 3
MU - Mauritius 3
PS - Palestinian Territory 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BY - Bielorussia 2
DK - Danimarca 2
HN - Honduras 2
IL - Israele 2
JM - Giamaica 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NO - Norvegia 2
OM - Oman 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AM - Armenia 1
BN - Brunei Darussalam 1
DZ - Algeria 1
FJ - Figi 1
Totale 27.180
Salva come PNG Salva come JPEG
Città #
Singapore 1.655
Southend 1.575
Ashburn 1.243
Fairfield 934
Chandler 899
Hong Kong 604
Houston 451
Wilmington 450
Woodbridge 430
Ho Chi Minh City 424
Seattle 413
San Jose 411
Santa Clara 409
Hanoi 400
Cambridge 345
Princeton 341
Beijing 299
Ann Arbor 279
Dublin 277
Hefei 253
Dong Ket 234
Boardman 224
Jacksonville 214
Los Angeles 166
Bologna 163
Lauterbourg 161
Helsinki 159
Lomé 154
Westminster 149
Abidjan 143
Padova 131
New York 129
Nanjing 127
Munich 121
Berlin 112
Tokyo 111
Seoul 110
Amman 102
Bern 100
Jinan 84
Dallas 80
Da Nang 79
Shenyang 76
Sofia 74
Saint Petersburg 71
Turin 67
Buffalo 64
Changsha 63
Florence 62
Frankfurt am Main 60
Redondo Beach 60
Milan 59
Haiphong 58
Guangzhou 55
Hebei 52
Bremen 48
Mülheim 47
Tianjin 47
San Diego 45
São Paulo 45
Abeokuta 44
Redmond 44
Nanchang 41
Shanghai 40
Jiaxing 38
Medford 38
Brussels 37
Zhengzhou 36
Johannesburg 34
Redwood City 34
Toronto 33
Chicago 30
Nuremberg 28
Falkenstein 27
Phoenix 27
Council Bluffs 26
London 26
Bengaluru 25
Dearborn 25
Des Moines 25
Norwalk 24
Biên Hòa 23
Hangzhou 23
Orem 23
Warsaw 23
The Dalles 22
Yubileyny 22
Baghdad 21
Brooklyn 21
Hải Dương 21
Mahé 21
Tongling 21
Jakarta 19
Taiyuan 19
Amsterdam 18
Haikou 18
Kuban 18
Wuhan 18
Atlanta 17
Can Tho 17
Totale 17.265
Salva come PNG Salva come JPEG
Nome #
Combined (18)F-FDG-PET/CT Imaging in Radiotherapy Target Delineation for Head-and-Neck Cancer. 439
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 337
18F-FDG PET early after radiotherapy in lymphoma patients. 315
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 308
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study 304
11-C-choline PET/CT imaging for localization of recurrent prostate cancer 291
11 C-CHOLINE-PET/CT FOR PREOPERATIVE N-STAGING IN HIGH RISK PROSTATE CANCER 262
A case of [68Ga]Ga-FAPI-46-avid and [18F]F-FDG-negative COVID-19 pneumonia sequelae 257
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 244
Molecular modelling evaluation of exon 18 His845_Asn848delinsPro pDGFRα mutation in a metastatic GIST patient responding to imatinib 233
Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. 232
11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. 229
11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. 227
(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. 224
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 221
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 220
Prediction Nomogram for 68 Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer 218
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 214
Identification of PET/CT radiomic signature for classification of locally recurrent rectal cancer: A network-based feature selection approach 213
Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). 210
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. 208
11C-CHOLINE PET/TC imaging for localization of recurrent prostate cancer 208
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 207
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 207
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. 207
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. 203
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 200
11C-Choline PET/CT for Restaging of Bladder Cancer 200
Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study 199
Pathological and molecular diagnosis of bilateral inguinal lymph nodes metastases from low-grade endometrial adenocarcinoma: a case report with review of the literature 199
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 199
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. 198
18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin 196
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 194
CT with 11C-Choline for identification of recurrent prostate cancer 192
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 192
18f-fdg pet/ct for restaging gastric cancer after surgical resection 190
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 188
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 187
PET-TC con 11C-colina e Spettroscopia di Risonanza Magnetica nella diagnosi e localizzazione del tumore prostatico: confronto con l'analisi seriata dello specimen chirurgico. 187
Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study 187
EFFETTO DELLA TERAPIA ORMONALE SULLA CAPTAZIONE DI 11-C-COLINA IN PAZIENTI CON RIPRESA DI MALATTIA DA CARCINOMA PROSTATICO 185
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. 185
Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer 184
Comparison between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. 184
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 184
Potential Prognostic Role of 18F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study 184
Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection 182
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 181
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 181
18 FDG-PET nel follow.up dei pazienti con carcinoma tiroideo differenziato 180
CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report 175
18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. 175
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 175
Image fusione between PET and CT for radiotherapy treatment planning for head and neck cancer 171
TOMOGRAFIA AD EMISSIONE DI POSITRONI CON 11-C-COLINA INTEGRATO A UN SISTEMA TC (11-C-CHOLINE-PET/TC) E RISONANZA MAGNETICA DI SPETTROSCOPIA DEL PROTONE (1-H-MRSI) NELLA DIAGNOSI DI NEOPLASIA PROSTATICA: STUDIO COMPARATIVO 171
[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy. 171
Evaluation of unusual neuroendocrine tumours by means of (68)Ga-DOTA-NOC PET. 169
11C-methionine vs. 18F-FDG PET in soft tissue sarcoma patients treated with neoadjuvant therapy: preliminary results 169
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. 167
Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of 68Ga-PSMA-11 in Patients with Prostate Cancer. 167
Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. 166
11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. 164
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 163
Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis 163
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. 162
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 161
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. 161
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 160
Sextant localization of prostate cancer:comparison between Magnetic Resonance Spectroscopic Imaging and 11C-Choline PET-CT. 159
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. 159
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. 159
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 159
Current Application and Future Perspectives of Prostate Specific Membrane Antigen PET Imaging in Prostate Cancer 159
Sextant localization of prostate cancer with 11-C-choline PET/CT: comparison with three-dimensional proton MR spectroscopic imaging using step section histopathology as standard of references 157
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. 157
POSITRON-EMISSION TOMOGRAPHY IN IMAGING AND STAGING PROSTATE CANCER 156
Pictorial essay: normal variants, lesions, and pitfalls in Ga-68-PSMA PET imaging of prostate cancer. 156
(18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. 155
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 155
Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL. 155
C–CHOLINE PET/CT IMAGING IS USEFUL FOR METASTATIC LYMPH NODES DETECTION IN NEWLY DIAGNOSED PROSTATE CANCER 154
Incidental finding of [68Ga]Ga-PSMA-avid intraductal papillary mucinous neoplasm 154
Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial 153
C–CHOLINE PET/CT IMAGING IS USEFUL FOR METASTATIC LYMPH NODES DETECTION IN NEWLY DIAGNOSED PROSTATE CANCER 152
Incidental finding of an (11)C-choline PET-positive solitary plasmacytoma lesion. 152
Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer 152
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 152
PET/TC CON 11-C-COLINA E SPETTROSCOPIA DO RISONANZA MAGNETICA NELLA DIAGNOSI E LOCALIZZAZIONE DEL TUMORE PROSTATICO: CONFRONTO CON LA ANALISI SERIATA DELLO SPICIMEN CHIRURGICO 151
Role of (11)C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy 151
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 151
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 151
Management of patients with gastrointestinal stromal tumor in clinical practice in Italy: a critical "event tree model" analysis of decision-making processes and outcomes. 151
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. 149
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 148
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database 148
Sextant localization of prostate cancer with 11-C-choline PET/CT: comparison with three-dimensional proton MR spectroscopic imaging using step section histopathology as standard of references 146
A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. 146
TOMOGRAFIA AD EMISSIONE DI POSITRONI CON 11-C-COLINA INTEGRATO A UN SISTEMA TC (11-C-CHOLINE-PET/TC) NELLA DIAGNOSI DI NEOPLASIA PROSTATICA 146
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 145
Totale 18.924
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021831 0 0 0 0 0 0 0 0 0 87 128 616
2021/20223.598 892 89 188 295 286 139 57 193 100 181 701 477
2022/20233.781 361 546 232 477 237 293 98 202 695 128 302 210
2023/20241.129 95 165 31 68 72 220 57 262 50 56 26 27
2024/20253.838 167 561 284 278 666 248 300 132 95 212 157 738
2025/20267.625 650 728 707 565 1.009 467 821 227 1.852 599 0 0
Totale 27.667